Should FTC Insulin Settlement And PBM Lawsuit Shift How Investors View CVS Health’s (CVS) Risk-Reward Profile?

Simply Wall St.03-26

CVS Health recently reached a proposed settlement with the Federal Trade Commission over insulin pricing practices in its Caremark pharmacy benefit manager unit, while also facing a new class action ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622001336?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/93625-main-header/1756253484610","is_english":true,"pubTime":"2026-03-26 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622001336","market":"nz","top_or_hot":-1,"title":"Should FTC Insulin Settlement And PBM Lawsuit Shift How Investors View CVS Health’s (CVS) Risk-Reward Profile?","media":"Simply Wall St.","content":"<div>\n<p>CVS Health recently reached a proposed settlement with the Federal Trade Commission over insulin pricing practices in its Caremark pharmacy benefit manager unit, while also facing a new class action ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/should-ftc-insulin-settlement-and-pbm-lawsuit-shift-how-inve\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should FTC Insulin Settlement And PBM Lawsuit Shift How Investors View CVS Health’s (CVS) Risk-Reward Profile?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould FTC Insulin Settlement And PBM Lawsuit Shift How Investors View CVS Health’s (CVS) Risk-Reward Profile?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 02:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/should-ftc-insulin-settlement-and-pbm-lawsuit-shift-how-inve><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CVS Health recently reached a proposed settlement with the Federal Trade Commission over insulin pricing practices in its Caremark pharmacy benefit manager unit, while also facing a new class action ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/should-ftc-insulin-settlement-and-pbm-lawsuit-shift-how-inve\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/should-ftc-insulin-settlement-and-pbm-lawsuit-shift-how-inve","article_id":"2622001336","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/93625-main-header/1756253484610"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cvs/cvs-health/news/should-ftc-insulin-settlement-and-pbm-lawsuit-shift-how-inve","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622001336","pubTimestamp":1774462482,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CVS Health recently reached a proposed settlement with the Federal Trade Commission over insulin pricing practices in its Caremark pharmacy benefit manager unit, while also facing a new class action lawsuit alleging improper formulary-related fees. \nAt the same time, CVS Health’s board affirmed its quarterly US$0.665 dividend and added former Elevance Health CFO John E. Gallina as an audit committee financial expert, underscoring governance and capital-return priorities amid regulatory...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","CVS.AU":"Cervantes Corp Ltd","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4551":"寇图资本持仓","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4211":"区域性银行","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","BK4196":"保健护理服务","BK4023":"应用软件","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4588":"碎股","BK4581":"高盛持仓","BK4543":"AI","AIPO":"Defiance AI and Power Infrastructure ETF","PBM":"Psyence Biomedical Ltd","AI":"C3.ai, Inc.","FTC":"First Trust Large Cap Growth Opp","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","ISBC":"投资者银行","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","BK4587":"ChatGPT概念","BK4528":"SaaS概念","CVS":"西维斯健康","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4504":"桥水持仓","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","AGIX":"通用人工智能 ETF-AGIX","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"FTC胰岛素和解和PBM诉讼是否会改变投资者对CVS Health(CVS)风险回报状况的看法？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FTC":1.5,"ISBC":1.5,"PBM":1.5,"AIYY":0.6,"AGIX":0.71,"AI":0.71,"CVS":1.5,"CVS.AU":1.5,"AIPO":0.81,"CHAT":0.71},"content_text":"CVS Health recently reached a proposed settlement with the Federal Trade Commission over insulin pricing practices in its Caremark pharmacy benefit manager unit, while also facing a new class action lawsuit alleging improper formulary-related fees.  At the same time, CVS Health’s board affirmed its quarterly US$0.665 dividend and added former Elevance Health CFO John E. Gallina as an audit committee financial expert, underscoring governance and capital-return priorities amid regulatory pressure on the PBM model. We’ll now examine how the FTC insulin settlement, alongside ongoing legal scrutiny of Caremark, may reshape CVS Health’s investment narrative. Uncover the next big thing with 30 elite penny stocks that balance risk and reward.AdvertisementCVS Health Investment Narrative RecapCVS Health’s appeal rests on its integrated model across insurance, pharmacy, and care delivery, and the belief that it can restore margins despite recent earnings pressure. The FTC insulin settlement and new Caremark class action keep regulatory and legal risk front and center, but do not directly alter the immediate earnings catalyst around stabilizing medical benefit ratios and pharmacy reimbursement; they mainly reinforce that the PBM business model is under close scrutiny. Among the latest developments, the board’s decision to maintain the quarterly US$0.665 dividend stands out in this context, signaling ongoing capital returns even as the PBM unit faces legal and regulatory challenges. Coupled with the appointment of former Elevance CFO John E. Gallina as an audit committee financial expert, CVS is emphasizing financial oversight and board-level expertise while it works through pressures in Medicare Advantage and pharmacy reimbursement. Yet against this backdrop, investors should be aware that ongoing legal and regulatory scrutiny of Caremark’s formulary practices could... Read the full narrative on CVS Health (it's free!)CVS Health's narrative projects $445.5 billion revenue and $10.2 billion earnings by 2029. This requires 3.7% yearly revenue growth and a $8.4 billion earnings increase from $1.8 billion today.Uncover how CVS Health's forecasts yield a $96.50 fair value, a 33% upside to its current price.Exploring Other PerspectivesCVS 1-Year Stock Price Chart Five members of the Simply Wall St Community value CVS Health between US$96.5 and US$283.96 per share, reflecting very different expectations. You should weigh that wide range against the current spotlight on Caremark’s legal and regulatory exposure and consider how it may affect CVS Health’s ability to lift margins in its core health insurance and PBM operations.Explore 5 other fair value estimates on CVS Health - why the stock might be worth over 3x more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your CVS Health research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.Want Some Alternatives?Our daily scans reveal stocks with breakout potential. Don't miss this chance:Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622001336","isCrawlerRequest":true}